UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus
UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus – Biobank Commentary: Covid: Antibodies last at least six months in most – BBC
The post UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus appeared first on Links Medicus.
Study shows the viral load of index cases is a leading driver of SARS-CoV-2 transmission
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study – The Lancet Infectious Diseases Commentary: Understanding the drivers of transmission of SARS-CoV-2 – The Lancet Infectious Diseases
The post Study shows the viral load of index cases is a leading driver of SARS-CoV-2 transmission appeared first on Links Medicus.
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Invited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
The post RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 appeared first on Links Medicus.
Covid-19: People who have had infection might only need one dose of mRNA vaccine
Covid-19: People who have had infection might only need one dose of mRNA vaccine – The BMJ Original preprint studies: Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine – medRxiv AND Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2 – medRxiv
The post Covid-19: People who have had infection might only need one dose of mRNA vaccine appeared first on Links Medicus.
Russia’s Sputnik V COVID-19 vaccine candidate appears safe and is 91.6% effective
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia – The Lancet Commentaries: Sputnik V COVID-19 vaccine candidate appears safe and effective – The Lancet AND Russia’s “Sputnik V” COVID Vaccine Makes Strong 91.6 % Efficacy Showing In Peer-Reviewed […]
The post Russia’s Sputnik V COVID-19 vaccine candidate appears safe and is 91.6% effective appeared first on Links Medicus.
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
The post Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma appeared first on Links Medicus.
Ambulatory management of pulmonary embolism: A comparison of two risk-stratification scores
Ambulatory Management of PE: A Comparison of Two Risk-Stratification Scores – American College of Cardiology
The post Ambulatory management of pulmonary embolism: A comparison of two risk-stratification scores appeared first on Links Medicus.
Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients
Post-COVID-19, CT Reveals Potentially Lifetime Lung Damage in One-Thirds of Patients – Diagnostic Imaging Original Study: Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia – Radiology
The post Post severe COVID-19, CT reveals potentially lifetime lung damage in one-thirds of patients appeared first on Links Medicus.
[Press release – not published yet] Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 trial
News release: Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial Commentaries: J&J’s one-shot COVID vaccine offers hope for faster protection – Nature AND Johnson & Johnson Executive Says Vaccine Works Where It Counts: Preventing Deaths – NPR AND Novavax’s COVID Vaccine Shows […]
The post [Press release – not published yet] Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 trial appeared first on Links Medicus.
New Updates to the Surviving Sepsis Campaign COVID-19 Guidelines
Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU – Critical Care Medicine Additional resources: COVID-19 Guidelines – Surviving Sepsis Campaign Commentary on Twitter New updates to the #SurvivingSepsis Campaign #COVID19 Guidelines! Includes new recommendations for therapeutics and defines severe vs critical COVID-19. View the full […]
The post New Updates to the Surviving Sepsis Campaign COVID-19 Guidelines appeared first on Links Medicus.